Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FIRSTx is a Phase 2, multicenter, randomized, open-label clinical trial evaluating the safety and efficacy of oral CXA-10 to treat immunosuppression-naïve patients 13 years of age and older with biopsy-confirmed primary FSGS.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2020
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CXA-10
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : National Heart, Lung, and Blood Institute | Complexa
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral CXA-10 in Pulmonary Arterial Hypertension
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2019
Lead Product(s) : CXA-10
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : National Heart, Lung, and Blood Institute | Complexa
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CXA-10
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Medpace, Inc | Innovative Analytics | Allegheny Singer Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2019
Lead Product(s) : CXA-10
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Medpace, Inc | Innovative Analytics | Allegheny Singer Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CXA-10
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Medpace, Inc | Philips | Cardiovascular Clinical Sciences | MicroConstants | Innovative Analytics | Allegheny Singer Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2018
Lead Product(s) : CXA-10
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Medpace, Inc | Philips | Cardiovascular Clinical Sciences | MicroConstants | Innovative Analytics | Allegheny Singer Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Kidney Research Network | Medpace, Inc | MicroConstants | Arkana Labs | NephCure Kidney International
Deal Size : Inapplicable
Deal Type : Inapplicable
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2018
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Kidney Research Network | Medpace, Inc | MicroConstants | Arkana Labs | NephCure Kidney International
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2015
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2015
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral CXA-10 Study in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2014
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2014
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of CXA-10 in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2014
Lead Product(s) : CXA-10
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable